Bank Of America Corp Iveric Bio, Inc. Transaction History

Bank Of America Corp

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	BUY	$26.24 - $39.63 $26.9 Million - $40.6 Million	1,024,205 Added 166.98%	1,637,560 $64.4 Million
Q1 2023 May 12, 2023	BUY	$18.67 - $24.56 $1.92 Million - $2.53 Million	102,915 Added 20.16%	613,355 $14.9 Million
Q4 2022 Feb 10, 2023	BUY	$17.24 - $23.95 $2.34 Million - $3.25 Million	135,596 Added 36.17%	510,440 $10.9 Million
Q3 2022 Nov 14, 2022	BUY	$9.4 - $18.59 $924,960 - $1.83 Million	98,400 Added 35.59%	374,844 $6.72 Million
Q2 2022 Aug 12, 2022	SELL	$9.12 - $18.9 $955,000 - $1.98 Million	-104,715 Reduced 27.47%	276,444 $2.66 Million
Q1 2022 May 16, 2022	BUY	$12.15 - $16.83 $2.43 Million - $3.36 Million	199,921 Added 110.31%	381,159 $6.41 Million
Q4 2021 Feb 08, 2022	BUY	$13.83 - $18.78 $2.12 Million - $2.88 Million	153,421 Added 551.54%	181,238 $3.03 Million
Q3 2021 Nov 15, 2021	SELL	$7.07 - $17.5 $227,045 - $561,995	-32,114 Reduced 53.58%	27,817 $451,000
Q2 2021 Sep 13, 2021	BUY	$5.69 - $7.17 $341,007 - $429,705	59,931 New	59,931 $378,000

250K

40K

Ticker ISEE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 118,078,000
Description
IVERIC bio, Inc., a biopharmaceutical company, discovers and develops novel treatments for retinal diseases with a focus on age-related and orphan inherited retinal diseases (IRDs). The company develops Zimura, an inhibitor of complement factor C5 comprising GATHER1, which has completed Phase 2/3 clinical trial; and GATHER2 that is in Phase 3 cl...

Get notified when there are updates to the investment portfolio of Bank Of America Corp , based on Form 13F filings with the SEC.

Stay updated on Bank Of America Corp with notifications on news.